C 6 Clinical trial issues in acute limb ischemia  by unknown
8164 C6 Clinical Trial Issues in AC1~te Limb Ischemia
JOURNAL OF VASCULAR SURGERY
January 2000
Critical Issue 26: Economic data on acute limb ischemia
There is a need for prospective studies documenting the costs of treating patients with
acute limb ischemia. To add significant data to this field, future studies should
• Define the duration and severity of ischemia
• Specify the etiology (thrombus/embolus)
• Prospectively compare, with randomization, the therapeutic options
• Document the use of resources (see Recommendation 7)
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C 6 Clinical Trial Issues in Acute Limb Ischemia
The appropriate treatment of acute limb ischemia is difficult to extract from the literature. This
is because of individual or institutional reports of the results of both surgical and thrombolytic
treatment either containing bias or not comparing with concurrent controls or not using stan-
dardized reporting practices. It is also because several recent trials comparing these two modali-
ties have, in retrospect, been seen to have serious flaws. Conversely, now that these are apparent,
guidelines for future trials can be developed that should further clarii}' the proper selection of
patients for treatment and the treatment of choice in specific settings. The following are some of
the critical issues in designing a trial in ALI, with examples of the problems that have been
encountered in the past.
C 6.1.1 Entry Criteria
The issue of entry criteria includes selection of patients for study by severity and duration of
ischemia, using appropriate inclusion/exclusion criteria, etc. The primary goal of treatment of
ALI is limb salvage. This and patient survival should be the main focus of most studies (see later
discussion of end points). However, many studies have included not only all patients with acute
thrombosis but even those with subacute and chronic thromboses, that is, including patients
regardless of the severity of ischemia and the need for or urgency of treatment.
For example, almost three quarters of the patients entered into the STILE trial had occlusions of
more than 14 days' duration1 Few of those under 14 days had class II acute limb-threatening
ischemia. One problem with such trials is that where a protocol is complex, with considerable time
needed to fully inform, register, and randomize the patient, it is difficult and bordering on unethi-
cal to include those needing immediate revascularization. This may be why a simpler single institu-
tional trial such as the Rochester trialwas the only one able to enter class II patients exclusively-
C 6.1.2 Intention-to-Treat Rule and Inclusion of Technical Failures
These basic prerequisites for a proper trial have often been neglected in the past, particularly in
retrospective, personal, or institutional series. It is impossible to be sure in the latter reports
how many cases of technical failures, for example, failure to gain access for CDT therapy, have
been eliminated. It may have been a more prevalent practice than suspected. After many encour-
aging reports of personal or institutional series claiming 75% to 85% success for CDT, it was a
rude awakening when most of the prospective randomized trials encountered a failure-to-gain-
access rate of close to 25%, from presumably well-selected participating centers. Undoubtedly,
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similar practices occur in reporting surgical experiences, but this highlighted an aspect of throm-
bolytic therapy that had not been fully appreciated.
Recommendation 66: Intention-to-treat analysis and technical failures in trials in acute
limb ischemia
• The intention-to-treat rule should be observed.
• Primary treatment failures (before treatment using another modality and including
teclmical failures) should be reported separately; with a categoricalbreakdown as to cause.
C 6.1.3 Stratification of Treatment Groups and Post Hoc Analysis
The word stratify may be used in two senses: to produce groups equivalent in risk factors for
controlled comparison of therapies or to separate groups by risk factors to test their respective
impact on therapeutic outcome. The latter meaning is used here. Because prospective random-
ized trials tend to be quite expensive, there is a tendency to avoid stratifyingpatients (ie, sepa-
rating them into several treatment groups by certain characteristics) to try to achieve statistical
positive results with the minimum number of subjects. This is clearlya "double-edged sword."
Power projections to determine the number of patients needed for statistical significance depend
on a predictable event rate (see C 6.1.7, Selection of End Points, p 5166) plus a good estimate
of the expected difference in end-point outcome between treatment or control groups.
Combining this with a hope for the widest popular application of the new treatment often
results in negative trials of a treatment that in truth is beneficial in certain selected patients,
something that only thoughtful stratification could prove.
There is no better example of this than the STILE trial (Surgery Versus Thrombolysis for
Ischemia of the Lower Extremity). Because of failure to stratify patients and the use of a com-
posite end point, the trialists were forced to use post hoc analysis of subgroups, which were not
prospectively identified, to try to show some benefit for eDT.l In retrospect, the trialists should
have separated:
• those with truly limb-threatening ischemia from those without
• those with very recent occlusions from those presenting after long delays
• those with native artery occlusions from those with graft occlusions, and those with occluded
vein grafts from those with occluded prosthetic grafts
• those with proximal (aortoiliac) from those with distal (infrainguinal) occlusive lesions
In some group comparisons, trends did not reach statistical significance, and in others statistical
significance was achieved but discounted because definition of the group was "post-hoc." It is
becoming increasingly evident that the distinction between a thrombotic and an embolic occlu-
sion often cannot be made before surgical exploration; therefore, pretreatment stratification on
this basis is unreliable.
Recommendation 67: Patient stratification in clinical trials in acute limb ischemia
• Different levels of ischemia should either not be combined in a study or should be
stratified beforehand.
• In addition to stratifying for the severity or duration of ischema, the following
should be studied either separately or together by using stratification as appropriate:
-native arteries and grafts
-vein and prosthetic grafts
C 6.1.4 Need for Standardized Reporting Practices
This applies to many aspects of the reported literature in this area, but the failure to identify the
level of ischemia of the patients treated and either select one level (II) or stratify for the levels,
has caused the most problems. Previous examples have been given from the prospective ran-
domized trials, but there are equivalent examples from retrospective, noncontrolled studies. For
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example, one study, which claimed 85% successful lysiswith an 8.3% amputation rate and 1.6%
mortality for all levels of ischemia, achieved patient and limb survival in 62.5% of class III level
"irreversible ischemia." The 100% success rate in classI and an 84% success rate with lysis alone
in class II, associated with no deaths and only an 8% amputation rate, were equally remarkable,
until it was seen that an ankle pressure of greater or less than 30 mm Hg. was a primary criteri-
on for separating these two groups, indicating that most of these cases did not have truly acute
limb-threatening ischemia.
Recommendation 68: Standardized reporting practices in acute limb ischemia
• Standard classification should be used for levels of ischemia.
• Standardized reporting practices should be used.
• Duration of ischemia should be reported as the basis for further stratification.
• Anatomic characteristics of underlying lesion should be reported.
C 6.1.5 Combining Treatments Within Groups
One of the major problems with trials of thrombolysis versus surgery for ALI is that comparisons
are not only made between thrombolysis versus thrombectomy for clot removal but include a
comparison of PTA versus surgery for the treatment of the underlying lesion. These treatments
are commonly linked in practice, so that thrombolysis is likely to be followed by PTA, and bypass
is likely to follow thrombectomy even if the underlying lesion is an arteriosclerotic narrowing.
There may even be an inherent bias in the choice of treatment of the underlying lesion. For exam-
ple, in the Rochester trial, performed by surgeons, most of the underlying lesions were treated by
surgery rather than PTA, which is quite the opposite of other trials. Though admittedly difficult to
control and dissociate, the effects of these separate components of therapy must be independently
assessed by the use of secondary end points, including a primary failure rate for initial therapy.
C 6.1.6 Control of Treatment Crossovers
This includes allowing for treatment crossovers in comparing treatment efficacy. In trials com-
paring surgery versus thrombolysis, because of the severity of the ischemia, and possibly even
immediate limb threat, thrombolysis failures are treated by surgery, with successful outcome
credited to thrombolysis, whereas surgical failures are not treated by thrombolysis and remain
failures. This apparent inequity is dismissed by some by pointing out that the goal of avoiding
surgical risk is a valid one. However, in most of the trials, the crossover to surgery is high; for
example, in the Rochester study- it was over 60%. Comparing primary therapeutic failures as an
additional end point would counteract the rnisimpression left by a high rate of unidirectional
treatment crossover.
Recommendation 69: Combining treatments within study groups
• The efficacy of the method of clot removal and the method of treating the underly-
ing lesion should be separated as much as possible. They may be independently
assessed by the use of secondary end points, including a primary failure rate for ini-
tial therapy.
• Subsequent treatment by the alternative modality (crossover) should not be arbi-
trary but strictly controlled by protocol and their rates reported.
C 6.1.7 Selection of End Points
The selection of appropriate end points takes skill and foresight. The goals of therapy are patient
and limb survival, and these should be the primary end points. Two end points may be appropri-
ately combined if measured at the same time. However, in the Rochester trial, the statisticallysig-
nificant mortality advantage to thrombolysis might have been lost if combined with limb loss,
because surgery and thrombolysis both had an 85% limb salvage rate at 1 year (albeit due to
surgery in over 60%of the thrombolysis cases). Combining more than two end points to achieve
statistical significance may be equally undesirable, particularly if they carry unequal weight. In the
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STILE trial, combining mortality, limb loss, major complications, and persistingor recurrent
ischemia into one combined clinical outcome end point achieved such statistical power that the
trial was stopped by the safety control committee before sufficient data could be accumulated to
allow statisticallysignificant subgroup analysis.'
Based on experience in previous trials in which there had been difficulty showing an advantage for
thrombolysis and a h.igh rate of crossover to surgery had been observed, TOPAS trialists believed
that even if the two treatments were not significantly different in the accepted end points of
patient survival and limb salvage, thrombolysis could be shown to hold an advantage if it reduced
the scope of the surgery performed.t In fact, a major claim of the TOPAS trialwas equivalence in
survival and limb salvage but reduced surgical risk. Unfortunately, the treatment severity scale used
was somewhat flawed. For example, a digital amputation was considereda greaterprocedure than
a bypass, and a direct bypasswas considered a greater procedure than a thromboembolectomy
with local revision (eg, endarterectomy or patch angioplasty). Neither of these is true in terms of
morbidity risk. Morbidity and success in relieving ischemia are valid secondary end points, but
these were pointedly left out of the TOPAS study after the experienceof the STILE trial.
Reconunendation 70: End points in trials .in acute limb ischemia
• Primary end points: Mortality and limb salvage are primary end points, the latter
only in class II level cases in which there is true limb threat. They may be combined.
• Secondary end points: Major morbidity and persisting/recurrent ischemia are appro
priate secondary end points, as is primary treatment failure. Reduction in the scope
or severity of ischemia are better assessed by standard morbidity assessments,
including length ofrray in an intensive care setting and in the hospital.
C 6.1.8 Adequate Follow-up
Thirty day or even 6-month outcomes may be insufficient, particularly if one treatment has a
shorter durability of success than the other. In the STILE trial, the initial report used these early
end points, but, considering the high rate of persistent or recurrent ischemia in the thromboly-
sis group, longer follow-up would be more appropriate. Short follow-up not only may con-
found life-table projections, but it does not allow the impact of re-treatment and its effect on
mortality, morbidity, limb loss, and costs to be properly included in the assessment.
Reconunendation 71: Duration of follow-up for trials in acute limb ischemia
Follow-up should be at least 6 months for meaningful comparisons of therapy.
C 6.1.9 Inclusion of Cost-effectiveness Analysis
Cost-effectiveness analysis is important, more so if the treatments end up being otherwise
equivalent. Rough cost analyses were done in two of the trials, showing no advantage to throm-
bolysis, possibly because of the frequent need to cross over to surgery. Formal analysis of actual
total costs, carried out at least to 1 year, are needed.
Recommendation 72: Cost-effectiveness analysis in trials in acute limb ischemia
Cost-effectiveness analysis should be included in trials comparing different treatments
of acute limb ischemia.
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